Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Strong Buy

Price to Earnings Rating

Strong Buy

Analyst Rating

Neutral

Simple Moving Average

Strong Sell

Exponential Moving Average

Strong Sell

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Neutral

Wall Street Data Solutions Rating

Neutral

B

Apellis Pharmaceuticals, Inc. Common Stock (APLS)

Pharmaceutical Preparations

https://www.apellis.com

Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3 the central protein in the complement cascade.

100 FIFTH AVENUE
WALTHAM, MA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

11/09/2017

Market Cap

4,563,789,680

Shares Outstanding

118,500,000

Weighted SO

118,499,945

Total Employees

N/A

Upcoming Earnings

11/06/2024

Similar Tickers

RXDX --.--%

AKRO --.--%

IMVT --.--%

MDGL --.--%

DAWN --.--%

MRTX --.--%

AMLX --.--%

TERN --.--%

XFOR --.--%

Beta

0.8720

Last Div

0.0000

Range

29.79-73.8

Chg

-0.1400

Avg Vol

1484535

Mkt Cap

4563789680

Exch

NASDAQ

Country

US

Phone

617 977 5700

DCF Diff

77.1353

DCF

-37.5353

Div Yield

0.0000

P/S

7.3899

EV Multiple

-14.4811

P/FV

17.5689

Div Yield %

0.0000

P/E

-13.9502

PEG

-1.3997

Payout

-0.0047

Current Ratio

5.0836

Quick Ratio

4.1805

Cash Ratio

2.1365

DSO

182.5393

DIO

644.4660

Op Cycle

827.0053

DPO

161.4413

CCC

665.5640

Gross Margin

0.8599

Op Margin

-0.5252

Pretax Margin

-0.5359

Net Margin

-0.5390

Eff Tax Rate

-0.0059

ROA

-0.3680

ROE

-1.3902

ROCE

-0.4411

NI/EBT

1.0059

EBT/EBIT

1.0204

EBIT/Rev

-0.5252

Debt Ratio

0.5124

D/E

1.7532

LT Debt/Cap

0.6337

Total Debt/Cap

0.6368

Int Coverage

141.0209

CF/Debt

-0.8810

Equity Multi

3.4218

Rec Turnover

1.9996

Pay Turnover

2.2609

Inv Turnover

0.5664

FA Turnover

30.6379

Asset Turnover

0.6828

OCF/Share

-3.2951

FCF/Share

-3.2994

Cash/Share

2.9812

OCF/Sales

-0.6611

FCF/OCF

1.0013

CF Coverage

-0.8810

ST Coverage

-65.7036

CapEx Coverage

-777.6800

Div&CapEx Cov

-195.8187

P/BV

17.5689

P/B

17.5689

P/S

7.3899

P/E

-13.9502

P/FCF

-11.1637

P/OCF

-11.3743

P/CF

-11.3743

PEG

-1.3997

P/S

7.3899

EV Multiple

-14.4811

P/FV

17.5689

DPS

0.0000

Latest Headlines (EST)

The Motley Fool May 07, 22:09 Why Apellis Pharmaceuticals Wilted on Wednesday Seeking Alpha Jan 15, 01:17 Many Layoffs Already Announced In 2024, Why? AI That's Why Seeking Alpha Jan 15, 01:17 Many Layoffs Already Announced In 2024, Why? AI That's Why Benzinga Jan 09, 10:00 Apellis Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (12 Ratings) Benzinga Dec 15, 08:15 Micron Technology To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Friday Benzinga Dec 05, 14:34 Apellis Pharmaceuticals Upgraded To Buy: Analyst Sees Potential In Syfovre's Strong Launch Benzinga Dec 05, 07:22 Block To Rally Around 54%? Here Are 10 Top Analyst Forecasts For Tuesday Seeking Alpha Nov 20, 00:24 Buy These Stocks; Members Of The Most Hated Tech Sector GlobeNewswire Inc. Nov 04, 13:37 SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 3 Years in Patients with Geographic Atrophy (GA) GlobeNewswire Inc. Nov 04, 13:37 SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 3 Years in Patients with Geographic Atrophy (GA) GlobeNewswire Inc. Nov 04, 13:37 SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 3 Years in Patients with Geographic Atrophy (GA) GlobeNewswire Inc. Nov 04, 13:37 SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 3 Years in Patients with Geographic Atrophy (GA) GlobeNewswire Inc. Nov 04, 13:37 SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 3 Years in Patients with Geographic Atrophy (GA) GlobeNewswire Inc. Nov 04, 13:37 SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 3 Years in Patients with Geographic Atrophy (GA) GlobeNewswire Inc. Nov 04, 13:37 SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 3 Years in Patients with Geographic Atrophy (GA) GlobeNewswire Inc. Nov 04, 13:37 SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 3 Years in Patients with Geographic Atrophy (GA) GlobeNewswire Inc. Nov 04, 13:37 SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 3 Years in Patients with Geographic Atrophy (GA) GlobeNewswire Inc. Nov 04, 13:37 SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 3 Years in Patients with Geographic Atrophy (GA) GlobeNewswire Inc. Nov 04, 13:37 SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 3 Years in Patients with Geographic Atrophy (GA) GlobeNewswire Inc. Nov 04, 13:37 SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 3 Years in Patients with Geographic Atrophy (GA)

Revenue Product Segmentation